Vorinostat
Histone Deacetylase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: suberoylanilide hydroxamic acid
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Vorinostat is an onp drug in the Histone Deacetylase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2006. Its mechanism of action is classified as Histone Deacetylase Inhibitors. DrugCentral lists 32 molecular targets, including HDAC6, HDAC1 and HDAC2. Recorded indications include Primary cutaneous T-cell lymphoma.
- Approval status: onp (first approved 2006 by the FDA).
- Drug class: Histone Deacetylase Inhibitor.
- Mechanism of action: Histone Deacetylase Inhibitors.
- Molecular targets: HDAC6, HDAC1, HDAC2 and HDAC3|NCOR2 (32 listed in DrugCentral).
- Indications: Primary cutaneous T-cell lymphoma.
- ATC code: L01XH01 (Histone deacetylase (HDAC) inhibitors).
- Molecular formula: C14H20N2O3; molecular weight 264.32 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Primary cutaneous T-cell lymphoma
Contraindications (18)
- Anemia
- Breastfeeding (mother)
- Congenital long QT syndrome
- Deep venous thrombosis
- Dehydration
- Diabetes mellitus
- Diarrhea
- Disease of liver
- Hyperglycemia
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Pregnancy, function
- Prolonged QT interval
- Pulmonary thromboembolism
- Thrombocytopenic disorder
- Thromboembolic disorder
- Vomiting
Mechanism & targets
| Mechanism of action (MoA) | Histone Deacetylase Inhibitors |
|---|---|
| Established pharmacologic class | Histone Deacetylase Inhibitor |
Molecular targets (32)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Histone deacetylase 6 | HDAC6 | inhibitor | Ki 9.00 |
| Histone deacetylase 1 | HDAC1 | inhibitor | Ki 8.89 |
| Histone deacetylase 2 | HDAC2 | inhibitor | Ki 8.80 |
| Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2) | HDAC3|NCOR2 | unknown | Ki 8.70 |
| Histone deacetylase 3 | HDAC3 | inhibitor | Ki 8.30 |
| Histone deacetylase (HDAC1 and HDAC2) | HDAC1|HDAC2 | unknown | IC50 8.00 |
| Histone deacetylase | HDAC3|HDAC4|HDAC1|HDAC7|HDAC2|HDAC10|HDAC11|HDAC8|HDAC6|HDAC9|HDAC5 | unknown | IC50 8.00 |
| Bromodomain-containing protein 4 | BRD4 | unknown | IC50 8.00 |
| Histone deacetylase 3/NCoR1 | HDAC3|NCOR1 | unknown | Ki 7.92 |
| Histone deacetylase 11 | HDAC11 | unknown | Ki 7.89 |
| Histone deacetylase 4 | HDAC4 | unknown | Ki 7.80 |
| Histone deacetylase | hd1b | unknown | IC50 7.55 |
| Histone deacetylase 5 | HDAC5 | unknown | Ki 7.48 |
| Histone deacetylase 9 | HDAC9 | unknown | Ki 7.31 |
| HD2 type histone deacetylase HDA106; Histone deacetylase 2b; Uncharacterized protein | hda106 | unknown | IC50 7.30 |
| Histone deacetylase 10 | HDAC10 | unknown | Ki 7.30 |
| Histone deacetylase | HDAC1 | unknown | IC50 7.23 |
| Histone deacetylase | PfHDAC1 | unknown | IC50 7.00 |
| Histone deacetylase 1/3/5/8 | HDAC3|HDAC1|HDAC8|HDAC5 | unknown | IC50 6.96 |
| Histone deacetylase 1 | Hdac1 | unknown | IC50 6.95 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2006-10-06 | FDA | — | MERCK | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01XH01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Histone deacetylase (HDAC) inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Febrile neutropenia | 283.7 |
| Thrombocytopenia | 173.0 |
| Product use in unapproved indication | 129.5 |
| Electrocardiogram QT prolonged | 107.5 |
| Lymphopenia | 91.2 |
| Dehydration | 91.1 |
| Torsade de pointes | 89.0 |
| Anaemia | 79.5 |
| Platelet count decreased | 74.6 |
| Sepsis | 73.2 |
| Neutropenia | 67.5 |
| Cutaneous T-cell lymphoma | 65.1 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Vorinostat is on its molecule page.
| Molecular formula | C14H20N2O3 |
|---|---|
| Molecular weight | 264.32 g/mol |
| CAS number | 149647-78-9 |
| InChIKey | WAEXFXRVDQXREF-UHFFFAOYSA-N |
| PubChem CID | 5311 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Vorinostat used for?
DrugCentral lists the following indications for Vorinostat: Primary cutaneous T-cell lymphoma.
How does Vorinostat work?
Vorinostat is classified as Histone Deacetylase Inhibitors; its molecular targets in DrugCentral include HDAC6 (inhibitor), HDAC1 (inhibitor), HDAC2 (inhibitor) and HDAC3|NCOR2.
When was Vorinostat first approved?
Vorinostat was first approved by the FDA in 2006.
What drug class does Vorinostat belong to?
Vorinostat is in the Histone Deacetylase Inhibitor class.
What is the chemical formula of Vorinostat?
Vorinostat has the molecular formula C14H20N2O3 and a molecular weight of 264.32 g/mol.
Browse: all drugs starting with V · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4124 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL98 — compound record and bioactivity
- PubChem CID 5311 — chemical identifiers
- DrugBank DB02546 — drug record
- FDA UNII 58IFB293JI — substance identity
- DailyMed: FDA labels for Vorinostat — current prescribing information (label search)
- UniProt Q9UBN7 (HDAC6) — target protein
- UniProt Q13547 (HDAC1) — target protein
- UniProt Q92769 (HDAC2) — target protein
- UniProt O15379 (HDAC3) — target protein
- UniProt O60885 (BRD4) — target protein
- UniProt Q96DB2 (HDAC11) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.